TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03468777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
Study: NCT02869334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Remediation
Description: Computer program designed to improve discrimination between sounds

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Remediation
Description: Computer program designed to improve discrimination between sounds

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control computer activities
Description: Computer program (e.g. games), which are not designed to improve discrimination between sounds
Study: NCT00421889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Study: NCT03468777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
Study: NCT00421889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03468777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
Study: NCT03149926

Intervention type: OTHER
Intervention: Stimuli presentation
Description: Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.

Intervention type: OTHER
Intervention: Stimuli presentation
Description: Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
Study: NCT01966263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the posterior capsule of the knee
Description: the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the posterior capsule of the knee
Description: the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the anterior capsule of the knee
Description: the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the subcutaneous tissue of the knee
Description: the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB with catheter
Description: pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
Study: NCT03296436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEOX® CORD 1K®
Description: NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
Study: NCT03290365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma + Hyaluronic acid
Description: Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: platelet rich plasma + normal saline
Description: The normal salin as the placebo intervention was injection control group.
Study: NCT03058419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 150 mg
Description: Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 600 mg
Description: Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Description: Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Description: Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 50 mg
Description: Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg
Description: Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study: NCT00776165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human GCSF (Shantha Biotechnics Limited)
Description: Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
Study: NCT04040153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guiding Good Choices
Description: Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
Study: NCT03468777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
Study: NCT00497952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoetic stem cell infusion
Description: Enriched hematopoietic stem cell infusion
Study: NCT00937820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT02603302

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalation Radiotherapy
Description: RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed surgery
Description: Surgery after 8 weeks with TME (total mesorectal excision)
Study: NCT00569621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxaverine
Description: intravenous administration
Study: NCT03468777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
Study: NCT00996658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching linagliptin tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin tablets once daily
Study: NCT04339413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab was administered as SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab was administered as SC injection Q4W.
Study: NCT01337193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises with biofeedback
Description: Exercises will be performed with assistance of biofeedback cueing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Exercises will b performed with verbal cueing of investigator.
Study: NCT02088853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat diet (hfd)
Description: Sixty % of the energy content is based on fat.
Study: NCT01515436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mozart alternating with Beethoven
Description: Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beethoven alternating with Mozart
Description: Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
Study: NCT02088853

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high carb diet
Description: Sixty % of the energy content is based on carbohydrates.
Study: NCT00903422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag olamine
Description: thrombopoietin receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with no active pharmaceutical ingredient
Study: NCT00581022

Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Overnight Sleep Study
Study: NCT00958477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
Study: NCT04003844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Coadministration
Study: NCT04571060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: One dose of zavegepant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matching placebo
Study: NCT02186483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,1000mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,1000mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,1000mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, 20 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, 20 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, 20 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
Study: NCT00442416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed, SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120-360 micrograms SC monthly, starting dose
Study: NCT03920241

Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/).

Intervention type: BEHAVIORAL
Intervention: Compassion Cultivation Training
Description: The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/).

Intervention type: OTHER
Intervention: Control Group
Description: A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
Study: NCT04115124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Action Research
Description: The research will employ a Participatory Action research quasi-experimental pre-post test study design .
Study: NCT04005495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching kitchen program
Description: The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
Study: NCT02487160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SBL-3 multifocal intraocular lens
Description: The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control monofocal intraocular lens
Description: The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
Study: NCT00295646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 20 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 20 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4 mg q6m

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4 mg q6m

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: 3.6 mg goserelin subcutaneously every 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: 3.6 mg goserelin subcutaneously every 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: 3.6 mg goserelin subcutaneously every 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: 3.6 mg goserelin subcutaneously every 28 days
Study: NCT02441101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD(R)-60 with AV optimization
Description: Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RV DDD(R)-60
Description: AV settings programmed to minimize RV pacing - standard demand pacing programming.
Study: NCT02075086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xelox or Xeliri Bevacizumab
Description: Chemotherapy treatment
Study: NCT04875494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling/support group therapy
Description: 6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
Study: NCT01603043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al-78898A
Description: 0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Mock injection administered as an empty hub without needle